← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Evon Medics, Llc
Elkridge, MD
$13,997,137
Total funding
7
Grants
Funding over time
peak $3.8M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,997,137 · 7
By mechanism
R44$13,322,137 · 5
R43$675,000 · 2
Investigators at Evon Medics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)$1,349,130
R44 · FY2024 · NS
The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR)$1,318,829
R44 · FY2023 · DA
Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)$1,280,870
R44 · FY2025 · NS
Development and Evaluation of Portable Compendium of Psychophysical and Physiological Tests for Alzheimer's Disease and Related Dementias (ADRD)$1,249,244
R44 · FY2024 · AG
Development and Evaluation of Portable Compendium of Psychophysical and Physiological Tests for Alzheimer's Disease and Related Dementias (ADRD)$1,249,244
R44 · FY2025 · AG
Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease (AD)$1,247,784
R44 · FY2021 · AG
Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease (AD)$1,245,116
R44 · FY2022 · AG
The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR)$1,219,088
R44 · FY2024 · DA
Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) for Opioid Use Disorder$859,103
R44 · FY2021 · DA
Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) for Opioid Use Disorder$820,883
R44 · FY2020 · DA
Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)$499,999
R44 · FY2022 · NS
Development and Evaluation of Portable Compendium of Psychophysical and Physiological Tests for Alzheimer's Disease and Related Dementias (ADRD)$448,887
R44 · FY2023 · AG
The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR)$330,680
R44 · FY2022 · DA
Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Preclinical and Early Alzheimer's Disease (AD)$225,000
R43 · FY2018 · AG
Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) for relapse preventionin patients with Opioid Use (OUD)$225,000
R43 · FY2019 · DA
Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Preclinical and Early Alzheimer's Disease (AD)$225,000
R43 · FY2019 · AG
Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease$98,280
R44 · FY2022 · AG
The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR)$55,000
R44 · FY2023 · DA
Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease (AD)$50,000
R44 · FY2022 · AG